Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Hodgkin Lymphoma|Metastatic Malignant Neoplasm|Metastatic Malignant Solid Neoplasm|Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colon Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colon Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colon Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Triple-Negative Breast Carcinoma|Unresectable Malignant Neoplasm|Unresectable Solid Neoplasm
Interventions: DRUG: Irinotecan Hydrochloride|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Veliparib
Sponsor: National Cancer Institute (NCI)